Altamira Therapeutics Ltd.

NasdaqCM:CYTO Stock Report

Market Cap: US$1.4m

Altamira Therapeutics Management

Management criteria checks 3/4

Altamira Therapeutics' CEO is Thomas Meyer, appointed in Apr 2003, has a tenure of 21.58 years. total yearly compensation is $778.61K, comprised of 55.9% salary and 44.1% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth $8.51K. The average tenure of the management team and the board of directors is 2.4 years and 7.1 years respectively.

Key information

Thomas Meyer

Chief executive officer

US$778.6k

Total compensation

CEO salary percentage55.9%
CEO tenure21.6yrs
CEO ownership0.6%
Management average tenure2.4yrs
Board average tenure7.1yrs

Recent management updates

Recent updates

Altamira Therapeutics completes enrollment in trial of its nasal spray to treat COVID

Sep 13

Altamira Therapeutics moving forward on plans to divest legacy assets, including Bentrio

Aug 30

Altamira starts development program for potential arthritis therapy

Jul 25

Altamira announces peer-reviewed publication on mRNA delivery platform

Jul 19

Altamira gains on peer-reviewed preclinical data publication for its RNA delivery platform

Jul 12

Auris Medical shares rise on OligoPhore Lymphoma study results

Jun 21

Auris Medical starts preparations for COVID-19 trial with Bentrio in India

Jun 01

Auris Medical updates on pollen challenge study for nasal spray

May 10

Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?

Dec 09
Are Insiders Buying Auris Medical Holding Ltd. (NASDAQ:EARS) Stock?

Auris Medical prices $8M direct equity offering, stock -22%

Dec 02

CEO Compensation Analysis

How has Thomas Meyer's remuneration changed compared to Altamira Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$779kUS$435k

-US$9m

Jun 30 2023n/an/a

-US$26m

Mar 31 2023n/an/a

-US$27m

Dec 31 2022US$690kUS$396k

-US$20m

Sep 30 2022n/an/a

-US$23m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$1mUS$401k

-US$7m

Sep 30 2021n/an/a

-US$16m

Jun 30 2021n/an/a

-US$13m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$741kUS$411k

-US$9m

Sep 30 2020n/an/a

-US$8m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$606kUS$376k

-US$7m

Sep 30 2019n/an/a

-US$9m

Jun 30 2019n/an/a

-US$11m

Mar 31 2019n/an/a

-US$12m

Dec 31 2018US$636kUS$370k

-US$12m

Sep 30 2018n/an/a

-US$13m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$19m

Dec 31 2017US$567kUS$373k

-US$25m

Compensation vs Market: Thomas's total compensation ($USD778.61K) is about average for companies of similar size in the US market ($USD647.72K).

Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.

CEO

Thomas Meyer (56 yo)

21.6yrs

Tenure

US$778,611

Compensation

Dr. Thomas Meyer, Ph.D. Founded Altamira Therapeutics Ltd. (formerly known as Auris Medical Holding Ltd.) (formerly known as Auris Medical Holding AG) in April 2003 and serves as Managing Director, Chairma...

Leadership Team

NamePositionTenureCompensationOwnership
Thomas Meyer
Founder21.6yrsUS$778.61k0.59%
$ 8.5k
Marcel Gremaud
Chief Financial Officer3yrsno data0.00094%
$ 13.6
Covadonga Paneda
Chief Operating Officer1.8yrsno datano data
Samuel Wickline
Chief Scientific Adviser1.8yrsno datano data

2.4yrs

Average Tenure

61yo

Average Age

Experienced Management: CYTO's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Thomas Meyer
Founder21.6yrsUS$778.61k0.59%
$ 8.5k
Alain Munoz
Independent Non-Executive Director6.7yrsUS$59.34k0.0082%
$ 118.3
Mats Blom
Independent Non-Executive Director7.6yrsUS$59.34k0.0082%
$ 118.7
Dominik Lysek
Directorless than a yearno datano data

7.1yrs

Average Tenure

59yo

Average Age

Experienced Board: CYTO's board of directors are considered experienced (7.1 years average tenure).